ATE261443T1 - 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen - Google Patents

3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen

Info

Publication number
ATE261443T1
ATE261443T1 AT98918598T AT98918598T ATE261443T1 AT E261443 T1 ATE261443 T1 AT E261443T1 AT 98918598 T AT98918598 T AT 98918598T AT 98918598 T AT98918598 T AT 98918598T AT E261443 T1 ATE261443 T1 AT E261443T1
Authority
AT
Austria
Prior art keywords
pyridyl
aza
bicyclo
azabicycloalkan
derivatives
Prior art date
Application number
AT98918598T
Other languages
English (en)
Inventor
William Scott Caldwell
Merouane Bencherif
Gary Maurice Dull
Peter Anthony Crooks
Patrick Michael Lippiello
Balwinder Singh Bhatti
Niranjan Madhukar Deo
Alain Ravard
Original Assignee
Targacept Inc
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/885,768 external-priority patent/US6624173B1/en
Priority claimed from US08/885,397 external-priority patent/US6525065B1/en
Application filed by Targacept Inc, Univ Kentucky Res Found filed Critical Targacept Inc
Application granted granted Critical
Publication of ATE261443T1 publication Critical patent/ATE261443T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98918598T 1997-06-30 1998-04-22 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen ATE261443T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/885,768 US6624173B1 (en) 1997-06-30 1997-06-30 Pharmaceutical compositions for treating and/or preventing CNS disorders
US08/885,397 US6525065B1 (en) 1997-06-30 1997-06-30 Pharmaceutical compositions and methods for effecting dopamine release
PCT/US1998/008145 WO1999000385A1 (en) 1997-06-30 1998-04-22 3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cns disorders

Publications (1)

Publication Number Publication Date
ATE261443T1 true ATE261443T1 (de) 2004-03-15

Family

ID=27128761

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98918598T ATE261443T1 (de) 1997-06-30 1998-04-22 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen

Country Status (10)

Country Link
EP (1) EP0994875B1 (de)
JP (1) JP2002511090A (de)
AT (1) ATE261443T1 (de)
AU (1) AU7149798A (de)
CA (1) CA2294990C (de)
DE (1) DE69822300T2 (de)
DK (1) DK0994875T3 (de)
ES (1) ES2214707T3 (de)
PT (1) PT994875E (de)
WO (1) WO1999000385A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
CA2389645A1 (en) * 1999-11-01 2001-05-10 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
AU2001286561B2 (en) * 2000-08-21 2007-02-08 Georgetown University 2-3-disubstituted quinuclidines as modulators of monoamine transporters and therapeutic and diagnostic methods based thereon
DE60136731D1 (de) 2000-09-20 2009-01-08 Ortho Mcneil Pharm Inc Pyrazine derivate als tyrosin kinase modulatoren
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
JP4923630B2 (ja) * 2006-03-02 2012-04-25 宇部興産株式会社 ４−置換テトラヒドロピランの製造方法
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5413441B2 (ja) * 2011-12-09 2014-02-12 宇部興産株式会社 ４−置換テトラヒドロピランの製造方法
CN104311514B (zh) * 2014-10-14 2016-06-22 安徽扬子化工有限公司 3-羟甲基四氢呋喃酯的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2022886A1 (en) * 1989-08-08 1991-02-09 Raymond Baker Substituted pyridines, their preparation, formulations and use in dementia
US5242935A (en) * 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
AU7474794A (en) * 1993-07-22 1995-02-20 E.I. Du Pont De Nemours And Company Arthropodicidal azacyclic heterocycles
US5510355A (en) * 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
AU5383196A (en) * 1995-05-17 1996-11-29 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders

Also Published As

Publication number Publication date
ES2214707T3 (es) 2004-09-16
JP2002511090A (ja) 2002-04-09
CA2294990C (en) 2007-03-06
CA2294990A1 (en) 1999-01-07
WO1999000385A1 (en) 1999-01-07
EP0994875B1 (de) 2004-03-10
AU7149798A (en) 1999-01-19
EP0994875A1 (de) 2000-04-26
DK0994875T3 (da) 2004-06-21
PT994875E (pt) 2004-06-30
DE69822300T2 (de) 2005-03-10
DE69822300D1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
Maelicke et al. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
PL1678172T3 (pl) Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego
WO2004108668A3 (en) Alpha-7 neuronal nicotinic receptor ligands: compositions and methods of use
DE60045427D1 (de) Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE69822300D1 (de) 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen
BG101806A (en) Indole derivatives as 5-ht receptor antagoniss
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
BG100830A (en) Naphthylamides as central nervous system agents
NO20041166L (no) Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament
DE68912419D1 (de) Verwendung von Uridin zur Behandlung nervöser Störungen.
IL192287A0 (en) Pharmaceutical compositions and methods for use
TNSN99177A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1, 2-a] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
TW200735868A (en) Compositions and methods for treating CNS disorders
AU4038000A (en) 4-substituted quinoline derivatives as gaba receptor ligands
WO2006040451A3 (fr) Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
NZ515613A (en) Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
HK1098670A1 (en) Use of 3-aza-1-oxa-dibenzo Äe,hÜ azulenes for the manufacture of pharmaceutical formulations for thetreatment and prevention of central nervous syste m disease and disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0994875

Country of ref document: EP

REN Ceased due to non-payment of the annual fee